AVITA Medical, Inc.
NasdaqCM:RCEL Stock Report
AVITA Medical Past Earnings Performance AVITA Medical's earnings have been declining at an average annual rate of -5.8%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 30.1% per year.
Key information
-5.8%
Earnings growth rate
Biotechs Industry Growth 17.0% Revenue growth rate 30.1% Return on equity -468.8% Net Margin -95.5% Last Earnings Update 30 Sep 2024
Recent past performance updates
Third quarter 2024 earnings: EPS misses analyst expectations Nov 08
AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 14
Full year 2023 earnings: EPS and revenues exceed analyst expectations Feb 23
Show all updates
AVITA Medical, Inc. Provides Financial Guidance for Fourth Quarter and Full Year of 2024 Nov 09
Third quarter 2024 earnings: EPS misses analyst expectations Nov 08
Forecast to breakeven in 2026 Nov 08
AVITA Medical, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 11
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too Oct 04
New minor risk - Shareholder dilution Aug 19
Consensus EPS estimates fall by 18% Aug 15
AVITA Medical, Inc. (NASDAQ:RCEL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Aug 11
New minor risk - Financial position Aug 09
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Forecast to breakeven in 2026 Aug 09
AVITA Medical, Inc. Provides Financial Guidance for Third Quarter 2024 and Updates Financial Guidance for Full Year 2024 Aug 09
AVITA Medical, Inc. Names Robin Vandenburgh as SVP of U.S. Commercial Sales Aug 02
AVITA Medical, Inc.'s (NASDAQ:RCEL) Share Price Boosted 26% But Its Business Prospects Need A Lift Too Jul 18
AVITA Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 12
New minor risk - Shareholder dilution Jul 10
AVITA Medical, Inc. Announces Executive Changes Jul 02
Is AVITA Medical (NASDAQ:RCEL) A Risky Investment? Jun 18
New minor risk - Shareholder dilution Jun 07
AVITA Medical, Inc. Announces FDA Approval of RECELL GO May 31
Consensus EPS estimates fall by 19% May 20
No longer forecast to breakeven May 15
AVITA Medical, Inc. Provides Earnings Guidance for the Second of 2024 May 15
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 14
AVITA Medical, Inc., Annual General Meeting, Jun 05, 2024 Apr 24
Little Excitement Around AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues As Shares Take 39% Pounding Apr 12
New minor risk - Share price stability Apr 11 AVITA Medical, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2024 and Full Year Fiscal 2024
AVITA Medical, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Feb 24
Full year 2023 earnings: EPS and revenues exceed analyst expectations Feb 23
AVITA Medical, Inc.'s (NASDAQ:RCEL) Price Is Right But Growth Is Lacking After Shares Rocket 39% Feb 02
AVITA Medical, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 02
Avita Medical, Inc. Provides Preliminary Revenue Guidance for Fourth Quarter and Full-Year 2023 and First Quarter and Year 2024 Jan 10
Forecast to breakeven in 2026 Dec 31
New minor risk - Insider selling Nov 16
New minor risk - Profitability Nov 13
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Nov 10
AVITA Medical, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 20
The Market Doesn't Like What It Sees From AVITA Medical, Inc.'s (NASDAQ:RCEL) Revenues Yet As Shares Tumble 32% Oct 20 AVITA Medical, Inc. announced that it expects to receive $90 million in funding from OrbiMed Advisors LLC
AVITA Medical, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023 Aug 11
AVITA Medical, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Jul 23
AVITA Medical, Inc. Submits FDA PMA Supplement for Recell Go Jun 30
AVITA Medical, Inc. Announces FDA Approval of RECELL for Skin Repigmentation in Vitiligo Patients Jun 17
AVITA Medical, Inc. Announces Appointment of David O’Toole as Chief Financial Officer Jun 16
AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects Jun 08
AVITA Medical, Inc. Expects FDA Submission of Recell Go by June 30, 2023 May 13
AVITA Medical, Inc. Announces Executive Changes May 12 AVITA Medical, Inc. to Report Q4, 2022 Results on Feb 23, 2023
AVITA Medical, Inc. Submits FDA PMA Application for Vitiligo Dec 20
AVITA Medical, Inc. Submits PMA Supplement for Soft Tissue Repair Dec 13
AVITA Medical, Inc. Revises Financial Guidance for the Year 2022 Nov 11
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL System for Soft Tissue Repair Nov 10
AVITA Medical, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 21
AVITA Medical, Inc., Annual General Meeting, Dec 12, 2022 Oct 20
AVITA Medical, Inc. Announces Executive Changes Sep 30
AVITA Medical, Inc. Announces Chief Executive Officer Changes Sep 29
Avita Medical appoints James Corbett as CEO Sep 29
AVITA Medical, Inc. Announces Positive Topline Results from A Pivotal Randomized, Controlled Trial Evaluating the Safety and Effectiveness of the RECELL® System for Repigmentation of Stable Vitiligo Lesions Sep 13
AVITA Medical says trial evaluating its RECELL system to treat vitiligo met main goal Sep 12
RECELL Insurance Coverage Begins in Japan for Acute Burns Sep 02
Avita's burn therapy Recell gets insurance coverage in Japan following approval Sep 01 AVITA Medical, Inc. Announces Topline Results from Pivotal Trial in Patients with Soft-Tissue Injuries Using the Recell System
AVITA Medical GAAP EPS of -$0.25 beats by $0.15, revenue of $8.34M beats by $1.18M Aug 11
AVITA Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 26 AVITA Medical, Inc.(NasdaqCM:RCEL) dropped from Russell 2000 Growth Index
Avita Medical, Inc. Provides Guidance for Year 2022 May 13
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors Apr 22
AVITA Medical, Inc. Provides Revenue Guidance for the Calendar Year 2022 Mar 01
AVITA (AVH) Announces RECELL Receives Japan PMDA Approval Feb 24
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use Feb 18
AVITA Medical, Inc. to Report First Half, 2022 Results on Feb 28, 2022 Feb 16 AVITA Medical, Inc. Establishes Proof of Concept for Gene Therapy
AVITA Medical Is Interesting, But Not Just Yet Dec 21
AVITA Medical, Inc. Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo Dec 16
AVITA Medical, Inc. Provides Revenue Guidance for the First Quarter of Fiscal Year 2022 Aug 27
FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical, Inc.'s Pivotal Study of the RECELL® System for Vitiligo Treatment Aug 17
AVITA Medical, Inc. Provides Revenue Guidance for the Fourth Quarter Ending June 30, 2021 Jun 18
Avita Medical, Inc. Announces Preliminary Unaudited Financial Results for the Fiscal Fourth Quarter Ending June 30, 2021 Jun 16
U.S. Food and Drug Administration Approves Expanded Use of the RECELL® System for the Treatment of Extensive Burns and Pediatric Patients Jun 11
AVITA Medical, Inc. Provides Earnings Guidance for 2021 May 14
AVITA Medical, Inc. Will Not Provide Financial Guidance At This Time Feb 12 AVITA Medical, Inc. to Report Q2, 2021 Results on Feb 11, 2021
AVITA Medical reports preliminary Q2 revenue in-line with consensus Jan 12
AVITA Therapeutics, Inc. Appoints Kathy McGee as Chief Operating Officer, Effective December 1, 2020 Dec 01
AVITA: COVID-19's Impact Nov 17
AVITA Therapeutics and the Houston Methodist Research Institute Enter into Collaboration to Explore Novel Approaches for Skin Rejuvenation Nov 09 AVITA Therapeutics, Inc. Announces Executive Changes
Revenue & Expenses Breakdown
How AVITA Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History NasdaqCM:RCEL Revenue, expenses and earnings (USD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Sep 24 60 -57 88 22 30 Jun 24 54 -50 80 21 31 Mar 24 51 -45 72 21 31 Dec 23 50 -35 66 21 30 Sep 23 45 -34 59 17 30 Jun 23 41 -31 53 17 31 Mar 23 37 -26 48 15 31 Dec 22 34 -27 45 14 30 Sep 22 32 -30 44 15 30 Jun 22 30 -30 43 14 31 Mar 22 32 -29 41 15 31 Dec 21 33 -25 38 16 30 Sep 21 31 -22 34 15 30 Jun 21 29 -27 37 15 31 Mar 21 23 -35 42 13 31 Dec 20 18 -44 50 11 30 Sep 20 16 -49 54 11 30 Jun 20 14 -42 49 9 31 Mar 20 12 -36 43 8 31 Dec 19 11 -28 35 7 30 Sep 19 8 -23 29 7 30 Jun 19 5 -25 28 8 31 Mar 19 4 -22 27 6 31 Dec 18 2 -18 17 10 30 Sep 18 1 -15 15 10 30 Jun 18 1 -13 16 6 31 Mar 18 1 -12 12 8 31 Dec 17 1 -11 12 7 30 Sep 17 1 -10 11 6 30 Jun 17 1 -9 11 5 31 Mar 17 1 -8 10 4 31 Dec 16 1 -7 8 3 30 Sep 16 1 -8 9 3 30 Jun 16 1 -8 8 3 31 Mar 16 1 -8 7 3 31 Dec 15 1 -7 5 3 30 Sep 15 1 -6 5 3 30 Jun 15 1 -6 4 3 31 Mar 15 1 -5 4 2 31 Dec 14 1 -5 5 2 30 Sep 14 2 -5 6 2 30 Jun 14 3 -5 7 2 31 Mar 14 3 -6 7 2 31 Dec 13 3 -7 8 2
Quality Earnings: RCEL is currently unprofitable.
Growing Profit Margin: RCEL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RCEL is unprofitable, and losses have increased over the past 5 years at a rate of 5.8% per year.
Accelerating Growth: Unable to compare RCEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RCEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: RCEL has a negative Return on Equity (-468.81%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
